STAT April 26, 2024
WASHINGTON — A House committee next month plans to mark up legislation that would restrict U.S. biotechnology companies from doing business with a Chinese company that makes key drug ingredients, according to five lobbyists tracking the BIOSECURE Act. The goal is for the House to pass the bill before the July 4 recess, setting it up to be included in a year-end must-pass legislative package.
The BIOSECURE Act was written by leaders of the Select Committee on the Chinese Communist Party,...
Today's Sponsors
Today's Sponsor